Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares reached a new 52-week low on Thursday . The stock traded as low as $1.50 and last traded at $1.56, with a volume of 1066925 shares trading hands. The stock had previously closed at $1.73.
Separately, ValuEngine raised Outlook Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, March 20th.
Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings results on Thursday, February 14th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($2.48) by $1.68. The business had revenue of $1.07 million for the quarter.
Outlook Therapeutics Company Profile (NASDAQ:OTLK)
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Featured Article: What are the components of an earnings report?
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.